Circulating and stool nucleic acid analysis for colorectal cancer diagnosis

World Journal of Gastroenterology

Volumn 20, Issue 4, 2014, Pages 957-967

  De Maio, Giulia ^a   Rengucci, Claudia ^a   Zoli, Wainer ^a   Calistri, Daniele ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Circulating DNA; Circulating RNA; Colorectal cancer; DNA integrity; Early diagnosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; DISEASE COURSE; HUMAN; MORBIDITY; MORTALITY; MUTATIONAL ANALYSIS; NUCLEIC ACID ANALYSIS; OCCULT BLOOD TEST; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CIRCULATING DNA; CIRCULATING RNA; COLORECTAL CANCER; DNA INTEGRITY; EARLY DIAGNOSIS;

ANIMALS; COLORECTAL NEOPLASMS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84892958389     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i4.957     Document Type: Article

References (108)

1. Mandel P, Metais P. [Les acides nucleiques du plasma sanguin chez l'Homme]. C R Seances Soc Biol Fil 1948; 142: 241-243 [PMID: 18875018]
2. Watson JD, Crick FH. A structure for deoxyribose nucleic acid. 1953. Nature 2003; 421: 397-398; discussion 396 [PMID: 12569935]
3. Tan EM, Schur PH, Carr RI, Kunkel HG. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966; 45: 1732-1740 [PMID: 4959277 DOI: 10.1172/JCI105479]
4. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002; 28: 255-271 [PMID: 12435372 DOI: 10.1016/S0305-7372(02)00077-4]
5. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650 [PMID: 837366]
6. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46: 318-322 [PMID: 2779946]
7. Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from Biomarkers Prev 1994; 3: 67-71 [PMID: 8118388]
8. Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994; 86: 774-779 [PMID: 7918071]
9. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999; 18: 65-73 [PMID: 10505546]
10. Sorenson GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000; 6: 2129-2137 [PMID: 10873061]
11. Kopreski MS, Benko FA, Borys DJ, Khan A, McGarrity TJ, Gocke CD. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000; 92: 918-923 [PMID: 10841827 DOI: 10.1093/jnci/92.11.918]
12. Yamada T, Nakamori S, Ohzato H, Oshima S, Aoki T, Higaki N, Sugimoto K, Akagi K, Fujiwara Y, Nishisho I, Sakon M, Gotoh M, Monden M. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998; 4: 1527-1532 [PMID: 9626473]
13. Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E, Solé M, Capellà G, Lluís F, Fernández-Cruz L, Navarro S, Farré A. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol 1999; 17: 578-584 [PMID: 10080602]
14. Ryan BM, Lefort F, McManus R, Daly J, Keeling PW, Weir DG, Kelleher D. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52: 101-108 [PMID: 12477769 DOI: 10.1136/gut.52.1.101]
15. Tong YK, Lo YM. Diagnostic developments involving cellfree (circulating) nucleic acids. Clin Chim Acta 2006; 363: 187-196 [PMID: 16126188 DOI: 10.1016/j.cccn.2005.05.048]
16. Kirsch C, Weickmann S, Schmidt B, Fleischhacker M. An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. Ann N Y Acad Sci 2008; 1137: 135-139 [PMID: 18837937 DOI: 10.1196/annals.1448.035]
17. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 2006; 12: 6985-6988 [PMID: 17145818 DOI: 10.1158/1078-0432.CCR-06-1931]
18. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665 [PMID: 11245480]
19. Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H. Degradation of chromosomal DNA during apoptosis. Cell Death Differ 2003; 10: 108-116 [PMID: 12655299 DOI: 10.1038/sj.cdd.4401161]
20. Viorritto IC, Nikolov NP, Siegel RM. Autoimmunity versus tolerance: can dying cells tip the balance? Clin Immunol 2007; 122: 125-134 [PMID: 17029966 DOI: 10.1016/j.clim.2006.07.012]
21. Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89-97 [PMID: 9667526]
22. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-3968 [PMID: 12873992]
23. Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Mueller SC, von Ruecker A. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 2008; 122: 138-143 [PMID: 17764114 DOI: 10.1002/ijc.23057]
24. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001; 313: 139-142 [PMID: 11694251]
25. Tuaeva NO, Abramova ZI, Sofronov VV. The origin of elevated levels of circulating DNA in blood plasma of premature neonates. Ann N Y Acad Sci 2008; 1137: 27-30 [PMID: 18837920 DOI: 10.1196/annals.1448.043]
26. Fournié GJ, Courtin JP, Laval F, Chalé JJ, Pourrat JP, Pujazon MC, Lauque D, Carles P. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995; 91: 221-227 [PMID: 7767913]
27. Swarup V, Rajeswari MR. Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases. FEBS Lett 2007; 581: 795-799 [PMID: 17289032 DOI: 10.1016/j.febslet.2007.01.051]
28. Rhodes CH, Honsinger C, Porter DM, Sorenson GD. Analysis of the allele-specific PCR method for the detection of neoplastic disease. Diagn Mol Pathol 1997; 6: 49-57 [PMID: 9028737]
29. Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, Stroun M, Anker P. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999; 5: 2297-2303 [PMID: 10499596]
30. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-1037 [PMID: 8782464]
31. Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer 2011; 105: 239-245 [PMID: 21712823]
32. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis 2007; 20: 408-411 [PMID: 17609601 DOI: 10.1097/QCO.0b013e32821f6010]
33. González-Masiá JA, García-Olmo D, García-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther 2013; 6: 819-832 [PMID: 23874104 DOI: 10.2147/OTT.S44668]
34. Wieczorek AJ, Sitaramam V, Machleidt W, Rhyner K, Perruchoud AP, Block LH. Diagnostic and prognostic value of RNA-proteolipid in sera of patients with malignant disorders following therapy: first clinical evaluation of a novel tumor marker. Cancer Res 1987; 47: 6407-6412 [PMID: 2445471]
35. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999; 5: 1961-1965 [PMID: 10473072]
36. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000; 6: 3823-3826 [PMID: 11051224]
37. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, Johnson PJ, Lo YM. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002; 48: 1212-1217 [PMID: 12142376]
38. Tsui NB, Ng EK, Lo YM. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002; 48: 1647-1653 [PMID: 12324479]
39. Hasselmann DO, Rappl G, Tilgen W, Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001; 47: 1488-1489 [PMID: 11468248]
40. Kopreski MS, Gocke CD. Cellular-versus extracellularbased assays. Comparing utility in DNA and RNA molecular marker assessment. Ann N Y Acad Sci 2000; 906: 124-128 [PMID: 10818607 DOI: 10.1111/j.1749-6632.2000.tb06601.x]
41. Ahnen DJ, Macrae FA. Colorectal cancer: Epidemiology, risk factors, and protective factors. 2013. Available from: URL: http://www.uptodate.com/contents/colorectal-cancerepidemiology-risk-factors-and-protective-factors#H33
42. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855]
43. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-793 [PMID: 16804544 DOI: 10.1038/ng1834]
44. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, Whitehall VL, Leggett BA, Laird PW. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009; 4: e8357 [PMID: 20027224]
45. Ji W, Hernandez R, Zhang XY, Qu GZ, Frady A, Varela M, Ehrlich M. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res 1997; 379: 33-41 [PMID: 9330620 DOI: 10.1016/j.bbr.2011.03.031]
46. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132: 127-138 [PMID: 17087942 DOI: 10.1053/j.gastro.2006.09.018]
47. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, Schroy PC, Sontag S, Johnson D, Markowitz S, Paszat L, Berger BM. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008; 103: 2862-2870 [PMID: 18759824]
48. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst 2005; 97: 1107-1109 [PMID: 16077063 DOI: 10.1093/jnci/dji244]
49. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, Lamerz R, Kolligs FT. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 142-149 [PMID: 15704048]
50. Kanthan R, Senger JL, Kanthan SC. Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract 2012; 2012: 184343 [PMID: 22969796 DOI: 10.1155/2012/184343]
51. Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G, Leo E, Pilotti S, Pierotti MA. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci 2006; 1075: 185-190 [PMID: 17108210 DOI: 10.1196/annals.1368.025]
52. Boni L, Cassinotti E, Canziani M, Dionigi G, Rovera F, Dionigi R. Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol 2007; 16 Suppl 1: S29-S31 [PMID: 18024018 DOI: 10.1016/]
53. Tomita H, Ichikawa D, Sai S, Morimura R, Murayama Y, Komatsu S, Ikoma D, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T, Kokuba Y, Sakakura C, Sonoyama T, Hagiwara A, Otsuji E. [Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal and gastric cancer]. Gan To Kagaku Ryoho 2007; 34: 1908-1910 [PMID: 18219849 DOI: 10.1016/j.suronc]
54. Kolesnikova EV, Tamkovich SN, Bryzgunova OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov PP, Rykova EY. Circulating DNA in the blood of gastric cancer patients. Ann N Y Acad Sci 2008; 1137: 226-231 [PMID: 18837952 DOI: 10.1196/annals.1448.009]
55. Catarino R, Ferreira MM, Rodrigues H, Coelho A, Nogal A, Sousa A, Medeiros R. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008; 27: 415-421 [PMID: 18694299 DOI: 10.1089/dna.2008.0744]
56. Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009; 11: 182-185 [PMID: 19324991]
57. Ellinger J, Müller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 2011; 29: 124-129 [PMID: 19762255]
58. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. Int J Cancer 2010; 127: 612-621 [PMID: 19960433 DOI: 10.1002/ijc.25077]
59. Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010; 116: 1674-1680 [PMID: 20143430 DOI: 10.1002/cncr.24893]
60. van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, van der Stappen JW, Dekhuijzen PN, van der Heijden HF, Thunnissen FB. Circulating DNA is a non-invasive prognostic factor for survival in nonsmall cell lung cancer. Lung Cancer 2010; 68: 283-287 [PMID: 19632736 DOI: 10.1016/j.lungcan.2009.06.021]
61. Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006; 1075: 299-307 [PMID: 17108224 DOI: 10.1196/annals.1368.040]
62. Hara M, Kanemitsu Y, Hirai T, Komori K, Kato T. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Dis Colon Rectum 2008; 51: 1675-1680 [PMID: 18633674 DOI: 10.1007/s10350-008-9406-1]
63. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560 [PMID: 12557158]
64. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52: 1062-1069 [PMID: 16723681]
65. Danese E, Montagnana M, Minicozzi AM, De Matteis G, Scudo G, Salvagno GL, Cordiano C, Lippi G, Guidi GC. Realtime polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers. Clin Chem Lab Med 2010; 48: 1665-1668 [PMID: 20704532 DOI: 10.1515/CCLM.2010.301]
66. Czeiger D, Shaked G, Eini H, Vered I, Belochitski O, Avriel A, Ariad S, Douvdevani A. Measurement of circulating cell-free DNA levels by a new simple fluorescent test in patients with primary colorectal cancer. Am J Clin Pathol 2011; 135: 264-270 [PMID: 21228367]
67. da Silva Filho BF, Gurgel AP, Neto MÁ, de Azevedo DA, de Freitas AC, Silva Neto Jda C, Silva LA. Circulating cellfree DNA in serum as a biomarker of colorectal cancer. J Clin Pathol 2013; 66: 775-778 [PMID: 23833048 DOI: 10.1136/jclinpath-2013-201521]
68. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res 2002; 8: 156-164 [PMID: 11801553]
69. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-2316 [PMID: 12174919]
70. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol 2004; 25: 228-234 [PMID: 15627885]
71. Liu Y, Tham CK, Ong SY, Ho KS, Lim JF, Chew MH, Lim CK, Zhao Y, Tang CL, Eu KW. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Biomarkers 2013; 18: 399-405 [PMID: 23862763]
72. Grützmann R, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, Bruch HP, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008; 3: e3759 [PMID: 19018278 DOI: 10.1371/journal.pone.0003759]
73. Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, Boardman LA, Berger BM, Lidgard GP. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 10: 272-7. e1 [PMID: 22019796 DOI: 10.1016/j.cgh.2011.10.008]
74. Yang H, Xia BQ, Jiang B, Wang G, Yang YP, Chen H, Li BS, Xu AG, Huang YB, Wang XY. Diagnostic value of stool DNA testing for multiple markers of colorectal cancer and advanced adenoma: a meta-analysis. Can J Gastroenterol 2013; 27: 467-475 [PMID: 23936877]
75. Amir S, Mabjeesh NJ. SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubuledisrupting agents. Cancer Biol Ther 2007; 6: 1926-1931 [PMID: 18075300]
76. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536 [PMID: 22722830 DOI: 10.1038/nature11156]
77. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 2008; 14: 7444-7451 [PMID: 19010861 DOI: 10.1158/1078-0432.CCR-08-0478]
78. Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini M, Digito M, Keppel S, Friso ML, Lonardi S, De Paoli A, Mescoli C, Nitti D, De Rossi A. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Ann Surg Oncol 2012; 19: 3089-3096 [PMID: 22395986 DOI: 10.1245/s10434-012-2272-z]
79. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5: 199-209 [PMID: 15738983 DOI: 10.1038/nrc1545]
80. Bader GM, Papanicolaou GN. The application of cytology in the diagnosis of cancer of the rectum, sigmoid, and descending colon. Cancer 1952; 5: 307-314 [PMID: 14905415]
81. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000; 31: 51-57 [PMID: 10665913]
82. Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998; 4: 337-342 [PMID: 9516920]
83. Baig MK, Stebbing JF, Marks CG. Anal canal metastases from left sided colorectal cancer. Colorectal Dis 2002; 4: 371-372 [PMID: 12780585 DOI: 10.1046/j.1463-1318.2002.00405.x]
84. Loktionov A. Cell exfoliation in the human colon: myth, reality and implications for colorectal cancer screening. Int J Cancer 2007; 120: 2281-2289 [PMID: 17351899 DOI: 10.1002/ijc.22647]
85. White V, Scarpini C, Barbosa-Morais NL, Ikelle E, Carter S, Laskey RA, Miller R, Coleman N. Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18: 2006-2013 [PMID: 19589912 DOI: 10.1158/1055-9965.EPI-08-1145]
86. Davies RJ, Freeman A, Morris LS, Bingham S, Dilworth S, Scott I, Laskey RA, Miller R, Coleman N. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002; 359: 1917-1919 [PMID: 12057556 DOI: 10.1016/S0140-6736(02)08739-1]
87. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-1816 [PMID: 7728743]
88. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227 [PMID: 11054379]
89. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53 [PMID: 12777192 DOI: 10.3816/CCC.2003.n.011]
90. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003; 1: 377-383 [PMID: 15017656]
91. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-1065 [PMID: 12816901 DOI: 10.1373/49.7.1058]
92. Calistri D, Rengucci C, Lattuneddu A, Francioni G, Polifemo AM, Nanni O, Saragoni L, Monti F, Ravaioli A, Zoli W, Amadori D. Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia 2004; 6: 536-540 [PMID: 15548362 DOI: 10.1593/neo.04190]
93. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, Syngal S, Lawson M, Shuber A. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004; 6: 386-395 [PMID: 15507679 DOI: 10.1016/S1525-1578(10)60536-3]
94. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectalcancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714 [PMID: 15616205 DOI: 10.1056/NEJMoa033403]
95. Kutzner N, Hoffmann I, Linke C, Thienel T, Grzegorczyk M, Urfer W, Martin D, Winde G, Traska T, Hohlbach G, Müller KM, Kuhnen C, Müller O. Non-invasive detection of colorectal tumours by the combined application of molecular diagnosis and the faecal occult blood test. Cancer Lett 2005; 229: 33-41 [PMID: 16157216]
96. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006; 15: 1115-1119 [PMID: 16775168 DOI: 10.1158/1055-9965. EPI-05-0992]
97. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S, Johnson D, Skoletsky J, Durkee K, Markowitz S, Shuber A. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5: 111-117 [PMID: 17161655 DOI: 10.1016/j.cgh.2006.10.006]
98. Abbaszadegan MR, Tavasoli A, Velayati A, Sima HR, Vosooghinia H, Farzadnia M, Asadzedeh H, Gholamin M, Dadkhah E, Aarabi A. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol 2007; 13: 1528-1533 [PMID: 17461444]
99. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149: 441-50, W81 [PMID: 18838724 DOI: 10.7326/0003-4819-149-7-200810 070-00004]
100. Calistri D, Rengucci C, Molinari C, Ricci E, Cavargini E, Scarpi E, Milandri GL, Fabbri C, Ravaioli A, Russo A, Amadori D, Silvestrini R. Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. Cell Oncol 2009; 31: 11-17 [PMID: 19096146]
101. Calistri D, Rengucci C, Casadei Gardini A, Frassineti GL, Scarpi E, Zoli W, Falcini F, Silvestrini R, Amadori D. Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals. Cancer Epidemiol Biomarkers Prev 2010; 19: 2647-2654 [PMID: 20929882 DOI: 10.1158/1055-9965.EPI-10-0291]
102. Kalimutho M, Del Vecchio Blanco G, Cretella M, Mannisi E, Sileri P, Formosa A, Pallone F, Federici G, Bernardini S. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. Int J Colorectal Dis 2011; 26: 583-592 [PMID: 21225430 DOI: 10.1007/s00384-010-112]
103. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, Butz ML, Thibodeau SN, Rabeneck L, Paszat LF, Kinzler KW, Vogelstein B, Bjerregaard NC, Laurberg S, Sørensen HT, Berger BM, Lidgard GP. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248-56; quiz e25-6 [PMID: 22062357 DOI: 10.1053/j.gastro.2011.10.031]
104. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004; 127: 422-427 [PMID: 15300574 DOI: 10.1053/j.gastro.2004.05.022]
105. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Kozu T, Baba H, Matsumura Y. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 2008; 99: 1977-1983 [PMID: 19016757 DOI: 10.1111/j.1349-7006.2008.00954]
106. Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A, Kanaoka S. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 2010; 102: 916-921 [PMID: 20145612 DOI: 10.1038/sj.bjc.6605564]
107. Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I. Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 455-458 [PMID: 18268130 DOI: 10.1158/1055-9965]
108. Olson J, Whitney DH, Durkee K, Shuber AP. DNA stabilization is critical for maximizing performance of fecal DNAbased colorectal cancer tests. Diagn Mol Pathol 2005; 14: 183-191 [PMID: 16106201]